Safety and Efficacy of FDC of Tamsulosin and Tadalafil in LUTS and Erectile Dysfunction

calendar
27 May, 24

 

Introduction

Studies have demonstrated that lower urinary tract symptoms (LUTS) independently increase the risk of erectile dysfunction (ED) in men. Phosphodiesterase type 5 inhibitors and α-adrenergic blocking agents (α-blockers) are widely used in the treatment of ED and LUTS associated with benign prostatic hyperplasia (BPH). The combination of these 2 classes of drugs seems to be safe and more effective in the treatment of LUTS with ED, rather than using each separately. Since the elderly people are likely to use multiple drugs for the treatment of other conditions such as hypertension, diabetes, etc, development of fixed-dose combination (FDC) can improve drug compliance. A combination of tamsulosin and tadalafil does not exert any changes in the blood pressure, making it safe in LUTS patients with ED.

Aim

To compare the efficacy and safety of FDCs of tamsulosin and tadalafil with tadalafil monotherapy in patients with comorbid BPH-associated LUTS and ED.

Method

Study Design

  • A randomized, double-blinded, active-controlled trial 

    Patient Profile

  • Men aged >50 years with BPH and ED for atleast 3 months
  • After the run-in period, Qmax of 4 to 15 ml/s and minimum voiding volume of atleast 125 ml
  • Postvoidal residual volume <300 ml
  • Coitus failure rate of atleast 50%
  • International index of erectile function (IIEF) erectile function domain score <25

Treatment Strategy

  • A total of 510 men with BPH-associated LUTS and ED were randomized into 3 groups receiving FDCs of tamsulosin 0.4 mg plus tadalafil 5 mg (FDC 0.4/5 mg), tamsulosin 0.2 mg plus tadalafil 5 mg (FDC 0.2/5 mg), or tadalafil 5 mg for a 12-week treatment period
  • The patients were administered FDC 0.4/5 mg for a subsequent 12-week extension period
  • The superiority and non-inferiority of FDCs in the treatment of LUTS and ED respectively was assessed
  • A clinically relevant difference of -2.2 points was considered for the superiority test for LUTS
  • For the non-inferiority test for ED, the assumed margin was -3.22
  • At week 24, the cohort underwent laboratory tests, and monitoring of vital signs

Endpoints

  • Changes from baseline in total International Prostate Symptom Score (IPSS) and IIEF-EF score at week 12
  • Incidence of adverse drug reactions (ADRs)

Results

  • FDC 0.4/5 mg demonstrated superiority in the LUTS treatment indicated by the mean change in total IPSS of -9.46 vs -8.14 for tadalafil 5 mg
  • FDC 0.4/5 mg was non-inferior to tadalafil 5 mg in ED treatment; IIEF-EF scores were 9.17 for FDC 0.4/5 mg and 9.49 for tadalafil 5 mg
  • The superiority of FDC 0.2/5 mg in LUTS improvement was not proven
  • The overall incidence of ADRs was 9.40% in the 12-week treatment period; 14.11%, 8.43% and 5.85% in FDC 0.4/5 mg, FDC 0.2/5 mg and tadalafil groups respectively
  • Incidence of ADRs was significantly higher in the FDC 0.4/5 mg group vs tadalafil group
  • However, most of the ADRs were of mild to moderate severity and resolved without any intervention
  • There were no clinically relevant changes in electrocardiogram, vital signs, laboratory tests or any physical examination

Conclusion

  • Fixed-dose combination (FDC) of tamsulosin 0.4 mg and tadalafil 5 mg was superior to tadalafil monotherapy in treatment of lower urinary tract symptoms (LUTS) and non-inferior in the treatment of erectile dysfunction (ED) in patients with comorbid benign-prostatic hyperplasia (BPH)-associated LUTS and ED.
  • FDC 0.4/5 mg therapy was effective, safe and well tolerated.

J Sex Med . 2017 Aug;14(8):1018-1027.